[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 511,164
  • Shares Outstanding, K 338,519
  • Annual Sales, $ 4,410 K
  • Annual Income, $ -67,850 K
  • EBIT $ -60 M
  • EBITDA $ -56 M
  • 60-Month Beta 2.30
  • Price/Sales 110.46
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 101.46% (-7.29%)
  • Historical Volatility 85.03%
  • IV Percentile 5%
  • IV Rank 3.38%
  • IV High 544.02% on 11/14/25
  • IV Low 86.00% on 01/08/26
  • Expected Move (DTE 4) 0.1275 (8.44%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 1,323
  • Volume Avg (30-Day) 2,163
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 81,276
  • Open Int (30-Day) 77,348
  • Expected Range 1.3825 to 1.6375

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 3
  • High Estimate $-0.04
  • Low Estimate $-0.05
  • Prior Year $-0.05
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3800 +9.42%
on 05/07/26
2.0350 -25.80%
on 04/17/26
-0.3500 (-18.82%)
since 04/08/26
3-Month
1.3100 +15.27%
on 02/09/26
2.7250 -44.59%
on 03/17/26
+0.1800 (+13.53%)
since 02/06/26
52-Week
0.6400 +135.94%
on 05/15/25
2.7250 -44.59%
on 03/17/26
+0.8206 (+119.03%)
since 05/08/25

Most Recent Stories

More News
Ocugen: Q1 Earnings Snapshot

Ocugen: Q1 Earnings Snapshot

OCGN : 1.5100 (+4.86%)
Ocugen Provides Business Update with First Quarter 2026 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p

OCGN : 1.5100 (+4.86%)
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due...

OCGN : 1.5100 (+4.86%)
Ocugen's Gene Therapy Timeline Finally Gets a Number Tomorrow

Barchart Research What to Expect from OCGN Earnings OCGN Generated May 4, 2026 Current Price $1.8500 EPS Estimate $$-0.05 Consensus Rating Strong Buy Average Move 6.53% Ocugen's Gene Therapy Timeline Finally...

OCGN : 1.5100 (+4.86%)
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

MALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

OCGN : 1.5100 (+4.86%)
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...

OCGN : 1.5100 (+4.86%)
Ocugen to Present at April 2026 Investor and Industry Conferences

MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...

OCGN : 1.5100 (+4.86%)
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

GARDian3 trial enrollment and dosing completed (N=63) in less than nine months Topline results expected in 2Q27 with BLA to follow by mid-2027 OCU410ST represents a potential first-in-class, one-time...

OCGN : 1.5100 (+4.86%)
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05) Potential 2X treatment benefit compared to 15% and 22%...

OCGN : 1.5100 (+4.86%)
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

OCGN : 1.5100 (+4.86%)

Business Summary

Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 1.6133
2nd Resistance Point 1.5667
1st Resistance Point 1.5383
Last Price 1.5100
1st Support Level 1.4633
2nd Support Level 1.4167
3rd Support Level 1.3883

See More

52-Week High 2.7250
Fibonacci 61.8% 1.9285
Fibonacci 50% 1.6825
Last Price 1.5100
Fibonacci 38.2% 1.4365
52-Week Low 0.6400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.